Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Practical optimization parameters for microvascular flow imaging (MVFI) in musculoskeletal ultrasound
| Parameter | Proposed setting | Rationale / Notes |
|---|---|---|
| Probe type | Linear high-frequency transducer | High spatial resolution of superficial structures |
| Recommended frequency |
| Balance between resolution and penetration according to depth |
| Pulse repetition frequency (PRF) | 0.4–1.0 kHz | Maximizes sensitivity to very-low-velocity flow; avoid aliasing by slight upward adjustment if necessary |
| Wall filter(11) | Minimal or “low” | Preserves slow-flow signals otherwise eliminated by clutter suppression |
| Gain | Increased gradually until noise just appears, then reduced by 2–3 dB | Ensures optimal signal-to-noise ratio without blooming artifacts |
| Frame rate | ≥40 frames/s | Allows stable motion subtraction and high temporal resolution |
| Dynamic range | Wide (60–70 dB) | Preserves subtle gradations in microvascular signal intensity |
| Persistence/compounding | Low to moderate | Prevents temporal blurring of fast microflow variations |
| Transducer pressure | Minimal, avoid tissue compression | Excessive pressure collapses capillaries and suppresses flow |
| Region of interest (ROI) | Fixed field (≈ 1 cm2 for small joints, 5 × 5 mm for intratendinous assessment); acquisition ≥3 s | Enables reproducible quantification and averaging of perfusion |
| Patient positioning | Relaxed, muscles at rest, avoid tendon tension | Reduces motion artifacts and physiologic compression |
| Documentation | Save ≥3 cine loops and static frames per site with parameters displayed | Facilitates reproducibility and quantitative vascular index computation |
MVFI findings in rheumatic diseases
| Condition | MVFI | Relevance |
|---|---|---|
| Rheumatoid arthritis (RA) |
| Indicates active synovitis and neoangiogenesis; predicts erosive progression and relapse; enables detection of subclinical inflammation and monitoring of therapeutic response |
| Seronegative RA / Early tenosynovitis |
| Reflects early inflammatory tenosynovitis and supports the diagnosis of seronegative or early RA before erosive damage |
| Psoriatic arthritis (PsA) |
| Reflects enthesitis and mixed axial–peripheral inflammation; differentiates PsA from RA; useful for biologic therapy monitoring |
| Juvenile idiopathic arthritis (JIA) |
| Improves sensitivity for active disease detection and therapy adjustment in pediatric rheumatology |
| Pigmented villonodular synovitis (PVNS) |
| Helps differentiate PVNS from RA; effusion predominance favors PVNS, while dense synovial vascularity favors RA |
| Gout |
| Differentiates crystal deposition from inflammatory pannus; confirms the non-neovascular nature of gouty tophi |
| Osteoarthritis(13) |
| Reflects low-grade synovial or capsular inflammation; vascularity correlates with pain and functional disability |
| Clinical remission |
| Confirms superior sensitivity of SMI for subclinical synovitis and its validity as a quantitative imaging biomarker of disease activity and remission |
Evolution of microvascular ultrasound findings in adhesive capsulitis
| Phase | MVFI findings | Capsular morphology | Clinical features |
|---|---|---|---|
| Freezing (Painful / Inflammatory) | Dense, arborizing microvascular signals within the rotator interval and capsule. | Capsule thickened and hypoechoic with mild effusion | Severe pain, progressive range- of-motion (ROM) loss (especially external rotation) |
| Frozen (Fibrotic / Stiff) | Focal or discontinuous low-grade flow; declining vascular index | Capsule thick, echogenic, reduced distensibility | Stiffness > pain; limited abduction and rotation |
| Thawing (Recovery) | No detectable microvascular flow | Fibrotic capsule thinning; reappearance of normal fascial planes | Gradual ROM improvement, minimal pain |